Antigen Characterized By Name Or Molecular Weight Patents (Class 424/156.1)
-
Patent number: 8821873Abstract: The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.Type: GrantFiled: October 3, 2013Date of Patent: September 2, 2014Assignee: Biogen Idec Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez
-
Patent number: 8815240Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: GrantFiled: March 18, 2009Date of Patent: August 26, 2014Assignee: China Synthetic Rubber CorporationInventors: Kuo-Jang Kao, Andrew T. Huang
-
Patent number: 8815242Abstract: The invention is drawn to a composition comprising an isolated mixture of cytotoxic anti-CD20 antibody molecules produced in a transgenic avian. The antibody molecules have a heavy chain and a light chain whose amino acid sequences set forth in SEQ ID NOs: 4 and 5 and exhibit an increased level of cytotoxicity as compared to anti-CD20 antibody molecules produced in CHO cells.Type: GrantFiled: May 27, 2010Date of Patent: August 26, 2014Assignee: Synageva BioPharma Corp.Inventor: Alex J. Harvey
-
Publication number: 20140227286Abstract: AnnexinA2 (ANXA2), a member of the Annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. AnnexinA2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane AnnexinA2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas. The cytoplasmic to cell surface translocation of AnnexinA2 expression is critical for pancreatic cancer cell invasion. In addition, phosphorylation of AnnexinA2 at Tyrosine 23 is important for its localization to the cell surface and for the invasion of pancreatic cancer cells. Finally, loss of AnnexinA2 leads to the loss of the Epithelial-Mesenchymal Transition.Type: ApplicationFiled: April 10, 2014Publication date: August 14, 2014Applicant: The Johns Hopkins UniversityInventors: Elizabeth Marion JAFFEE, Lanqing HUANG, Lei ZHENG
-
Patent number: 8802103Abstract: Monoclonal antibodies that specifically bind to an extracellular domain of human Jagged 1 and inhibit growth of a tumor comprising cancer stem cells are described. Also described is a method of treating cancer that comprises administering a therapeutically effective amount of a monoclonal anti-Jagged 1 antibody.Type: GrantFiled: May 15, 2008Date of Patent: August 12, 2014Assignee: OncoMed Pharmaceuticals, Inc.Inventors: Austin Gurney, Timothy Hoey, Sanjeev Satyal, Maureen Fitch Bruhns
-
Publication number: 20140220013Abstract: Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin.Type: ApplicationFiled: October 21, 2013Publication date: August 7, 2014Applicant: University of Louisville Research Foundation, Inc.Inventors: Paula J. Bates, Donald M. Miller, John Q. Trent, Xiaohua Xu
-
Publication number: 20140199242Abstract: Novel antibodies for the detection and/or treatment of a cancer (e.g., a pancreatic cancer or an ovarian cancer) are provided. In certain embodiments the antibodies bind a region of the MUC4 protein that does not comprise the central tandem repeat (TR) domain of MUC4. Certain antibodies bind to the MUC4 peptide fragment MUC4-?-N-Ter and/or to the MUC4 peptide fragment MUC4-?-C-Ter. Chimeric constructs comprising such antibodies are also provided.Type: ApplicationFiled: June 6, 2012Publication date: July 17, 2014Applicant: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKAInventors: Surinder K. Batra, Maneesh Jain, Moorthy P. Ponnusamy
-
Patent number: 8771695Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.Type: GrantFiled: April 15, 2010Date of Patent: July 8, 2014Assignees: U3 Pharma GmbH, Amgen, Inc.Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
-
Patent number: 8765124Abstract: Protein formulations containing a poloxamer as a surfactant, and methods for maintaining the biological activity in protein formulations without adding an antioxidant and for inhibiting the formation of foreign insoluble matters by adding a poloxamer as a surfactant.Type: GrantFiled: February 27, 2004Date of Patent: July 1, 2014Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Akihiko Saito, Eiichi Miyauchi
-
Patent number: 8765919Abstract: The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3 antibodies and TOX3 nucleic acids for both detection and modulation of TOX3. The invention also provides for pharmaceutical compositions and methods for the modulation of TOX3 in a subject in need thereof. Further aspects of the invention relate to transgenic mice that either over-express or inducibly express TOX3.Type: GrantFiled: June 4, 2012Date of Patent: July 1, 2014Assignee: Cedars-Sinai Medical CenterInventor: Jonathan Kaye
-
Patent number: 8753630Abstract: A set of markers for cancer stem cells are provided. The cells can be prospectively isolated or identified from primary tumor samples, and possess the unique properties of cancer stem cells in functional assays for tumor initiation, cancer stem cell self-renewal and differentiation. In addition, cancer stem cells can be used as a predictor for disease progression. The CSC have the phenotype of being positive for expression of CD133, and for EGFRvIII. In another embodiment of the invention, compositions are provided of a bispecific reagent that recognizes CD133 and EGFRvIII, including bispecific antibodies, which are optionally conjugated to a detectable marker, chemotherapeutic agent are radionuclide for imaging or therapy.Type: GrantFiled: February 12, 2009Date of Patent: June 17, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventor: Albert J. Wong
-
Publication number: 20140161814Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen.Type: ApplicationFiled: August 5, 2013Publication date: June 12, 2014Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventor: Nai-Kong V. CHEUNG
-
Patent number: 8741586Abstract: The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor. The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6). The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.Type: GrantFiled: December 6, 2010Date of Patent: June 3, 2014Assignees: Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats, Fundacio Privada Institut d'Investigacio Oncologica de vall d'HebronInventors: Joaquin Arribas Lopez, Kim Pedersen, Pier-Davide Angellini, Josep Lluis Parra Palau, Jose Baselga Torres
-
Publication number: 20140134180Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to O8E with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: ApplicationFiled: November 7, 2013Publication date: May 15, 2014Applicant: MEDAREX, L.L.C.Inventors: ALAN J. KORMAN, MARK J. SELBY, LI-SHENG LU, ALISON J. WITTE, HAICHUN HUANG
-
Patent number: 8722051Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: GrantFiled: December 19, 2012Date of Patent: May 13, 2014Assignee: Immunex CorporationInventor: Steven R. Wiley
-
Publication number: 20140127226Abstract: Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector/memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.Type: ApplicationFiled: December 13, 2013Publication date: May 8, 2014Applicants: St. Jude's Children's Research Hospital Inc., The Johns Hopkins UniversityInventors: Drew M. PARDOLL, Ching-Tai HUANG, Jonathan POWELL, Charles DRAKE, Dario A. VIGNALI, Creg J. WORKMAN
-
Publication number: 20140099325Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: ApplicationFiled: June 18, 2013Publication date: April 10, 2014Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Publication number: 20140093514Abstract: The present invention relates to MAGEA3 binding antibodies.Type: ApplicationFiled: May 23, 2012Publication date: April 3, 2014Applicants: University of Zurich, CT ATLANTIC LTD.Inventors: Christoph Esslinger, Michael Höcker, Martin Treder, Alexander Knuth, Elke Jäger
-
Patent number: 8679500Abstract: The present invention relates to compositions containing antibodies for treating CD5+ HLA-DR+ B OR T cell related diseases such as B or T cell malignances (leukaemia and lymphoma), autoimmune diseases and T cell related diseases as transplantation and graft rejection.Type: GrantFiled: May 14, 2010Date of Patent: March 25, 2014Assignees: Institute National de la Sante et de la Recherche Medicale (INSERM), Universite de Bretagne Occidentale, Centre National de la Recherche Scientifique (CNRS)Inventors: Laurence Boumsell, Christian Berthou, Karine Lester, Severine Loisel, Martine Cerruti
-
Patent number: 8673309Abstract: A method of detecting MSDX Complex-1, the method introducing a first antibody to a sample to create an antibody-sample mixture, wherein the first antibody is specific for one of fibrinogen, fibronectin, or fibulin-1, the first antibody having a label molecule; providing a well coated with a second antibody, the second antibody is specific for one of fibrinogen, fibronectin, or fibulin-1; introducing the antibody-sample mixture to the well; and introducing a substrate to the antibody-sample mixture in the well, wherein the label molecule and the substrate interact to provide a signal, wherein when the signal is detected then MSDX Complex-1 is detected.Type: GrantFiled: February 10, 2012Date of Patent: March 18, 2014Assignee: MSDx, Inc.Inventor: Ramesh C. Nayak
-
Publication number: 20140065148Abstract: Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach.Type: ApplicationFiled: July 8, 2013Publication date: March 6, 2014Applicant: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran
-
Patent number: 8658168Abstract: This invention discloses monoclonal antibodies (MAbs) which have little or no signaling activity as monomers become potent anti-tumor agents when they are converted into homoconjugates. The homoconjugates exert anti-growth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and does not require an Fc portion. These conjugates are potent, anti-tumor agents.Type: GrantFiled: April 8, 2002Date of Patent: February 25, 2014Assignee: The Board of Regents of The University of Texas SystemInventors: Maria-Ana Ghetie, Jonathan W. Uhr, Ellen S. Vitetta
-
Patent number: 8652467Abstract: The present invention relates to DEK protein compositions (e.g., antibodies, small molecule inhibitors, siRNAs) and methods of using the same. In particular, the present invention provides compositions and methods for treating autoimmune disease (e.g., juvenile rheumatoid arthritis, lupus, etc.) and for inhibiting inflammation (e.g., associated with autoimmune disease) and cellular chemotaxis (e.g., of neutrophils, NK cells and T cells). The present invention further provides a diagnostic marker (e.g., DEK antigen) for autoimmune disease.Type: GrantFiled: October 16, 2006Date of Patent: February 18, 2014Assignee: The Regents of the University of MichiganInventors: David M. Markovitz, Nirit Mor-Vaknin, Michael Khodadoust, Barbara S. Adams
-
Patent number: 8652473Abstract: The present invention relates generally to growth factor receptor epitope peptides, particularly EGF family receptor epitope peptides. The invention also relates to the use of the receptor peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against the receptor peptides. Methods for generating an immune response and for treatment of tumors and cancer are also provided.Type: GrantFiled: January 29, 2010Date of Patent: February 18, 2014Assignees: Ludwig Institute for Cancer Research Ltd., Massachusetts Institute for Technology, Commonwealth Scientific and Industrial Research OrganizationInventors: Terrance Grant Johns, Andrew Mark Scott, Antony Wilks Burgess, Lloyd J. Old, Timothy E. Adams, K. Dane Wittrup, Ginger Chao, Peter Anthony Hoyne
-
Patent number: 8652474Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.Type: GrantFiled: January 28, 2009Date of Patent: February 18, 2014Assignee: Genentech, Inc.Inventors: Reed J. Harris, Paul A. Motchnik
-
Publication number: 20140044639Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.Type: ApplicationFiled: August 15, 2013Publication date: February 13, 2014Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20140037644Abstract: The invention provides methods for treating cancer via administering to a patient having a solid tumor a therapeutically effective amount of an antibody against Delta-like ligand 4(Dll4) or other Notch pathway components. The solid tumor may comprise solid tumor stem cells.Type: ApplicationFiled: March 12, 2013Publication date: February 6, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventor: THE REGENTS OF THE UNIVERSITY OF MICHI
-
Patent number: 8642036Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.Type: GrantFiled: August 2, 2004Date of Patent: February 4, 2014Assignee: Genentech, Inc.Inventor: Susan D. Hellmann
-
Patent number: 8642032Abstract: The present invention provides a method for screening a patient to be administered with a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient, said method comprising collecting samples from patients who expresses an antigen which is recognized by the anti-cancer antibody, measuring cadherin function in the samples, and selecting a patient whose the cadherin function is decreased or deleted; a method for screening a patient who has a high efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient; and a method for improving an efficacy ratio for a pharmaceutical composition which comprises an anti-cancer antibody as an active ingredient.Type: GrantFiled: June 26, 2008Date of Patent: February 4, 2014Assignees: Kyowa Hakko Kirin Co., Ltd., Japan as Represented by President of National Cancer CenterInventors: Takashi Sato, Naoya Kimoto, Yuji Ohki, Akiko Furuya, Hiroyuki Ishida, Atsushi Ochiai
-
Patent number: 8637012Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: November 15, 2011Date of Patent: January 28, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 8623354Abstract: The present invention relates generally to treatment and prophylactic protocols for cellular diseases or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides compositions comprising therapeutic antibodies and hyaluronan and their use in the treatment or prophylaxis of cellular diseases and disorders.Type: GrantFiled: September 4, 2006Date of Patent: January 7, 2014Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Publication number: 20140004124Abstract: It is disclosed herein that condroitin sulfate proteoglycan 4 (CSPG4), also known as high molecular weight melanoma associated antigen, is overexpressed on basal breast carcinoma cells (BBC), specifically triple negative basal breast carcinoma cells (TNBC). Methods for detecting basal breast cancer in a subject are disclosed. Methods are also disclosed for inhibiting the growth of a basal breast cancer cell. These methods include contacting the basal breast cancer cell with an effective amount of an antibody that specifically binds CSPG4. Additional treatment methods, and the use of antibody panels, are also described herein.Type: ApplicationFiled: June 18, 2013Publication date: January 2, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Soldano Ferrone, Xinhui Wang
-
Patent number: 8614301Abstract: Anti-CD24 antibodies and adjuvant combinations thereof with chemotherapeutic agents or toxins, which can be used to inhibit growth of CD24-expressing cancer cells and prevent and treat cancer are provided.Type: GrantFiled: November 13, 2008Date of Patent: December 24, 2013Assignee: The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical CenterInventor: Nadir Arber
-
Publication number: 20130336967Abstract: BST2 antibodies were selected by using as an indicator the binding between BST2 antibodies and various splicing variants of human BST2 antigen. As a result, the present inventors successfully obtained BST2 antibodies that specifically recognize BST2D, which has been reported to be expressed at high levels in cancer cells. The antibodies of the present invention specifically bind to cells expressing BST2D. Non-specific antibody binding to non-target tissues, which results in the decrease of antibody concentration in blood, can be prevented by using the antibodies of the present invention therapeutically. Alternatively, the present invention provides diagnostic agents comprising an antibody of the present invention, which specifically detect tissues expressing BST2D.Type: ApplicationFiled: August 22, 2013Publication date: December 19, 2013Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, SBI BIOTECH CO., LTD.Inventors: YUMIKO KAMOGAWA, SAHORI NAMIKI, MINKWON CHO, KOJI ISHIDA
-
Publication number: 20130336886Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.Type: ApplicationFiled: May 25, 2011Publication date: December 19, 2013Applicant: UNC-CHARLOTTEInventor: Pinku Mukherjee
-
Publication number: 20130330333Abstract: This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.Type: ApplicationFiled: February 10, 2012Publication date: December 12, 2013Applicant: The Rockefeller UniversityInventors: Sohail Tavazoie, Nils Halberg, Kim Png
-
Patent number: 8597645Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.Type: GrantFiled: October 6, 2011Date of Patent: December 3, 2013Assignee: New York UniversityInventors: Robert Schneider, Sumayah Jamal
-
Publication number: 20130315820Abstract: An antibody directed against the BDCA-2 protein for the prevention or the treatment of the pathologies involving activation of the plasmacytoid dendritic cells.Type: ApplicationFiled: December 12, 2011Publication date: November 28, 2013Applicant: LFB BIOTECHNOLOGIESInventors: Nathalie Fournier, Christophe Romeuf
-
Patent number: 8591897Abstract: The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.Type: GrantFiled: April 6, 2006Date of Patent: November 26, 2013Assignee: Genentech, Inc.Inventor: John L. Bryant
-
Patent number: 8586042Abstract: The present invention provides anti-mortalin peptide antibodies having stronger anticancer effects than known anti-mortalin antibodies, hybridomas producing such antibodies, and anticancer agents using such antibodies. Specifically, a hybridoma C-26 strain (FERM P-21875) and a hybridoma C-69 strain (FERM P-21876) producing anti-mortalin monoclonal antibodies having the function of being internalized by cancer cells and specificity to mortalin antigens, and having the good function of suppressing the cancer cell proliferation in vivo were obtained from hybridoma clones obtained using as an immunogen cocktail of the 2 types of peptide containing “LFGRAP” and “KAMQDAEVSKSDIGEVI” epitopes for an anti-mortalin antibody having the function of being internalized by cancer cells. Thus, anticancer agents containing the monoclonal antibodies as active ingredients could also be provided. Moreover, the epitope sequences recognized by these monoclonal antibodies were confirmed to be “EVILVG” and “DLFGR.Type: GrantFiled: December 9, 2010Date of Patent: November 19, 2013Assignee: National Institute of Advanced Industrial Science and TechnologyInventors: Renu Wadhwa, Sunil Kaul
-
Patent number: 8586041Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: May 11, 2009Date of Patent: November 19, 2013Assignee: Genmab A/SInventors: Jan G. J. van de Winkel, Marcus Antonius van Dijk, Edward Halk, Arnout F. Gerritsen, Jorgen Petersen, Ole Baadsgaard
-
Publication number: 20130302317Abstract: The present invention relates to agents capable of binding sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) and their use in the treatment of cell proliferation and differentiation disorders. Furthermore, the present invention provides associated pharmaceutical formulations and methods.Type: ApplicationFiled: March 12, 2013Publication date: November 14, 2013Applicant: University Court of the University of DundeeInventors: Paul Richard Crocker, Bjoern Biedermann, David Bowen
-
Patent number: 8562997Abstract: Methods are provided to manipulate phagocytosis of cancer cells, including e.g. leukemias, solid tumors including carcinomas, etc.Type: GrantFiled: July 15, 2010Date of Patent: October 22, 2013Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Siddhartha Jaiswal, Irving L. Weissman, Ravindra Majeti, Mark P. Chao
-
Patent number: 8563692Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?) or interferon beta (IFN-?).Type: GrantFiled: January 5, 2011Date of Patent: October 22, 2013Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
-
Patent number: 8557244Abstract: This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.Type: GrantFiled: July 28, 2000Date of Patent: October 15, 2013Assignee: Biogen Idec Inc.Inventors: Christine White, Antonio Grillo-Lopez
-
Publication number: 20130259873Abstract: Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.Type: ApplicationFiled: December 1, 2011Publication date: October 3, 2013Inventors: Soldano Ferrone, Xinhui Wang, Elvira Favoino, Ling Yu, Yangyang Wang
-
Publication number: 20130251705Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells.Type: ApplicationFiled: February 22, 2013Publication date: September 26, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: John A. LEWICKI, Austin Gurney, Timothy Hoey, Wan-ching Yen, Sanjeev Satyal
-
Publication number: 20130236449Abstract: The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.Type: ApplicationFiled: April 21, 2011Publication date: September 12, 2013Applicant: VENTIRX PHARMACEUTICALS, INC.Inventor: Robert Hershberg
-
Publication number: 20130230512Abstract: The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.Type: ApplicationFiled: March 11, 2013Publication date: September 5, 2013Applicant: Georgia Health Sciences University Research Institute, Inc.Inventor: Georgia Health Sciences University Research Institute, Inc.
-
Publication number: 20130230535Abstract: This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection.Type: ApplicationFiled: April 9, 2013Publication date: September 5, 2013Inventor: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH